Fennec Pharmaceuticals Inc., a biopharmaceutical company, focuses on cancer therapeutics. Lead Product Candidate The company’s only primary product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), a water soluble thiol compound that acts as a chemical reducing agent that completed patient enrollment of two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company has licensed from Oregon Health & Science University (OHSU) intellectual property rights for the use of STS as a chemoprotectant, and is developing STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children. Preclinical and clinical studies conducted by OHSU and others have indicated that STS could reduce the incidence of hearing loss caused by platinum-based anti-cancer agents. The company received Orphan Drug Designation in the United States for the use of STS in the prevention of platinum-induced ototoxicity in pediatric patients. STS has been studied by cooperative groups in two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. SIOPEL 6 In 2007, the company announced that its collaborative partner, the International Childhood Liver Tumour Strategy Group, known as SIOPEL, a multi-disciplinary group of specialists under the umbrella of the International Society of Pediatric Oncology, had launched a randomized Phase III clinical trial (SIOPEL 6) to investigate whether STS reduces hearing loss in standard risk hepatoblastoma (liver) cancer patients receiving cisplatin as a monotherapy. The study was initiated in October 2007 initially in the United Kingdom and through the end of 2014, 45 sites from 12 countries enrolled 109 evaluable patients. COG ACCL0431 In 2008, the company announced the activation of a Phase III trial with STS to prevent hearing loss in children receiving cisplatin-based chemotherapy in collaboration with the Children’s Oncology Group (COG ACCL0431). The goal of this Phase III study is to evaluate in a multi-centered, randomized trial whether STS is an effective and safe means of preventing hearing loss in children receiving cisplatin-based chemotherapy for newly diagnosed germ cell, liver (hepatoblastoma), brain (medulloblastoma), nerve tissue (neuroblastoma) or bone (osteosarcoma) cancers. Intellectual Property The company has licensed from Oregon Health and Science University one U.S. and nine foreign patents, with an additional one patent pending. Research and Development The company’s research and development expenses totaled $0.3 million for the year ended December 31, 2015. History Fennec Pharmaceuticals Inc. was founded in 1996. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in 2014. It was incorporated under the Canada Business Corporations Act in 1996.
fennec pharmaceuticals inc
(FRX:Toronto Stock Exchange)
68 TW Alexander Drive
PO Box 13628
Research Triangle Park, NC 27709
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for FRX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact FENNEC PHARMACEUTICALS INC, please visit www.fennecpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.